Description

PAVmed Inc. functions as a medical technology enterprise based in the United States. Its primary offerings feature CarpX, a patented, single-use, disposable, and minimally invasive surgical tool developed for addressing carpal tunnel syndrome. The company also provides EsoCheck, an esophageal cell collection device facilitating the early identification of esophageal adenocarcinoma and Barrett's Esophagus (BE), along with EsoGuard, an advanced DNA assay utilizing bisulfite-converted next-generation sequencing. Moreover, the firm's developmental pipeline encompasses EsoCure, an esophageal ablation device aimed at treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and the Veris cancer care platform. Founded in 2014, the corporation initially operated under the name PAXmed Inc., subsequently adopting its current designation, PAVmed Inc., in April 2015. Its corporate headquarters are located in New York, New York.